DMACDiaMedica Therapeutics Inc.

DMAC Stock Price, Valuation & Chart | DiaMedica Therapeutics Inc.

Compare

$6.750+0.30 (+4.65%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology DMAC intrinsic value DMAC calculated fair value vs price

Overview Financials Dividends Ratios

DMAC Historical price chart

DMAC Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization363.71M

PE Ratio-9.51

EPS-0.71

Trading Volume175.98K

Today's High/Low6.86/6.59

Dividend Yield0.00

52 Week High/Low10.42/5.14

Shares Outstanding53.88M

DMAC Financial Statement

DMAC Analyst ratings

DMAC Analysis & performance metrics

DMAC Company profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199,…

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3…

DMAC Management team

Name

Position

Alex Aimetti Ph.D.

Chief Development Officer

Dietrich John Pauls MBACEO

President, Chief Executive Officer & Director

Lorianne K. Masuoka M.D.

Chief Medical Officer

Scott Kellen CPACFO

Chief Financial Officer & Corporate Secretary

Ambarish Shah Ph.D.CTO

Chief Technology Officer

Dominic R. Cundari

Chief Commercial Officer

David J. Wambeke

Chief Business Officer

Name

Position

Alex Aimetti Ph.D.

Chief Development Officer

Dietrich John Pauls MBACEO

President, Chief Executive Officer & Director

Lorianne K. Masuoka M.D.

Chief Medical Officer

Scott Kellen CPACFO

Chief Financial Officer & Corporate Secretary

Ambarish Shah Ph.D.CTO

Chief Technology Officer

Dominic R. Cundari

Chief Commercial Officer

David J. Wambeke

Chief Business Officer

Management Team

Alex Aimetti Ph.D.

Chief Development Officer

Dietrich John Pauls MBACEO

President, Chief Executive Officer & Director

Lorianne K. Masuoka M.D.

Chief Medical Officer

Scott Kellen CPACFO

Chief Financial Officer & Corporate Secretary

Ambarish Shah Ph.D.CTO

Chief Technology Officer

Dominic R. Cundari

Chief Commercial Officer

David J. Wambeke

Chief Business Officer

Management

Alex Aimetti Ph.D.

Chief Development Officer

Dietrich John Pauls MBACEO

President, Chief Executive Officer & Director

Lorianne K. Masuoka M.D.

Chief Medical Officer

Scott Kellen CPACFO

Chief Financial Officer & Corporate Secretary

Ambarish Shah Ph.D.CTO

Chief Technology Officer

Dominic R. Cundari

Chief Commercial Officer

David J. Wambeke

Chief Business Officer

Total 7 executives

DMAC Frequently asked questions

What is DiaMedica Therapeutics Inc. (DMAC) Stock Price?

Current stock price of DiaMedica Therapeutics Inc. (DMAC) stock is $6.750. The stock price is +4.65% higher in the session. The intraday range can be seen from this page. Volume of DiaMedica Therapeutics Inc. (DMAC) stock is 175.98K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the DiaMedica Therapeutics Inc. (DMAC) stock price going up or down today?

The stock price of DiaMedica Therapeutics Inc. (DMAC) can change with earnings, company news, and overall market sentiment. DiaMedica Therapeutics Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the DiaMedica Therapeutics Inc. stock expensive at its current price?

Whether DiaMedica Therapeutics Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for DMAC on this page is -9.51. EPS on this page is -0.71. Compare those figures with peers and growth expectations before deciding if the current DiaMedica Therapeutics Inc. price is justified.

How has the stock price of DiaMedica Therapeutics Inc. (DMAC) performed historically?

Historical performance for DiaMedica Therapeutics Inc. (DMAC) is shown on the price chart on this page. Review multi-period moves alongside volume to see how DMAC reacted to past earnings and market events.

Should I buy DiaMedica Therapeutics Inc. (DMAC) stock, at this price?

Buying DiaMedica Therapeutics Inc. (DMAC) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.